Non-interventional study on the efficiency of Erbitux in the first-line therapy in patients with metastatic colorectal cancer with wild-type KRAS gene

Trial Profile

Non-interventional study on the efficiency of Erbitux in the first-line therapy in patients with metastatic colorectal cancer with wild-type KRAS gene

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ERBITAG
  • Sponsors Merck Serono
  • Most Recent Events

    • 28 Sep 2016 According to the Merck KGaA media release, the company will present data from this trial at the ESMO 2016.
    • 11 Apr 2016 New trial record
    • 23 Jan 2016 Interim analysis (n=497) presented at the 2016 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top